Uveal Melanoma Biology, Biomarkers for Metastatic Risk and Personalized Treatment

Dear Colleagues,

There has been tremendous progress in knowledge regarding the (epi-)genomic and transcriptomic signatures of primary uveal melanoma. We can now profile these tumors up to a single cell level and provide detailed biomarker signatures. Using clinical information alongside these signatures, we can accurately classify tumors and can estimate prognosis in the range of low, mid, and high risk. We are now in the unique position of being able to explore individual patients’ germline DNA and tumor biology and provide a more detailed individual risk prediction, as well as evaluate and predict response to treatment options. Additionally, we can use this knowledge to improve our understanding of the processes behind metastasis and, for instance, develop noninvasive monitoring programs. In this Special Issue, experts in the field will contribute their science and insights into the biological mechanisms behind uveal melanoma metastasis, in vitro and in vivo experiments to elucidate uveal melanoma biology, signaling cascades to target using various interventions, and the uveal melanoma microenvironment and methods to accurately predict individual risk and treatment strategies.

Dr. Erwin Brosens
Dr. Emine Kilic
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.